SAN DIEGO, Oct. 31, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, November 7, 2016 at 5:00 p.m. ET to report its third quarter 2016 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 6469174. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]


Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



